TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Vital HEAT (vH2) Temperature Management System to Upper-body Forced-air Warming

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body-mass index 20-36 kg/m2;~* Age 18-75 yrs;~* ASA Physical Status 1-3.~Exclusion Criteria:~* Patient requires an intravenous or arterial catheter distal to the elbow on both arms;~* Serious skin lesions on the hands or arms;~* History of serious vascular disease in the arms;~* Pre-operative fever;~* Contraindication to sevoflurane endotracheal anesthesia.~* Pre-existing neuropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vital Heat (Type: ACTIVE_COMPARATOR): Vital HEAT (vH2) Temperature Management System
- Forced air (Type: ACTIVE_COMPARATOR): Forced-air warming

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~Participants with hypercholesterolemia and established coronary heart disease (CHD) or CHD risk equivalents who are not adequately controlled with a maximally tolerated daily dose of statin at a stable dose for at least 4 weeks prior to the screening visit (Week -3).~Exclusion criteria:~* Participants without established CHD or CHD risk equivalents.~* LDL-C \<70 mg/dL (\<1.81 mmol/L) at the screening visit (Week -3) in participants with history of documented CV disease.~* LDL-C \<100 mg/dL (\<2.59 mmol/L) at the screening visit (Week -3) in participants without history of documented CV disease.~* Change in statin dose or dose regimen from screening to randomization.~* Currently taking a statin other than atorvastatin, rosuvastatin, or simvastatin.~* Atorvastatin, rosuvastatin, or simvastatin was not taken daily or not taken at a registered dose.~* Daily doses above atorvastatin 80 mg, rosuvastatin 40 mg, or simvastatin 40 mg.~* Use of cholesterol absorption inhibitor (ie, ezetimibe), omega-3 fatty acid (at doses ≥1000 mg daily), nicotinic acid, fibrates, bile acid-binding sequestrant, or red yeast rice products in the past 4 weeks prior to screening visit (Week -3).~* Fasting serum triglycerides \>400 mg/dL (\>4.52 mmol/L) at the screening period.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ezetimibe 10 mg (Type: ACTIVE_COMPARATOR): Oral ezetimibe 10 mg capsule once daily with or without food for 24 weeks and subcutaneous placebo injection for alirocumab every 2 weeks (Q2W) for 22 weeks added to lipid modifying therapy (LMT).
- Alirocumab 75 mg Q2W/up to 150 mg Q2W (Type: EXPERIMENTAL): Subcutaneous injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe once daily with or without food added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C level was \>=70 milligrams per deciliter (mg/dL) (1.81 millimoles per liter \[mmol/L\]) at Week 8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Definite MS diagnosis according to McDonald's criteria;~* Relapsing clinical course, with or without progression;~* Expanded Disability Status Scale \[EDSS\] less or equal to 5.5 (ambulatory);~* Stable dose of Glatiramer Acetate \[GA\] for at least 26 weeks prior to the screening visit;~* No onset of MS relapse in the preceding 60 days prior to randomization;~* Clinically stable for 4 weeks prior to randomization.~Exclusion Criteria:~* Other chronic disease of the immune system, liver function impairment or chronic pancreatic disease;~* Pregnant or nursing woman;~* Alcohol or drug abuse;~* Use of cladribine, Mitoxantrone, or other immunosuppressant agents such as Azathioprine, Cyclophosphamide, Cyclosporin, Methotrexate or Mycophenolate before enrollment;~* Human immunodeficiency virus \[HIV\] positive status;~* Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + GA (Type: PLACEBO_COMPARATOR): Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate (GA) for 24 weeks
- Teriflunomide 7 mg + GA (Type: EXPERIMENTAL): Teriflunomide 7 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
- Teriflunomide 14 mg + GA (Type: EXPERIMENTAL): Teriflunomide 14 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Couple-Based Treatment for Alcohol Use Disorders and Post-Traumatic Stress Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Veteran must meet Diagnostic and Statistical Manual of Mental Disorders (DSM-IV; American Psychiatric Association, 1994) criteria for current (past 12 months) alcohol abuse or dependence and alcohol must be the Veteran's primary substance of abuse as determined by a clinical algorithm (Fals-Stewart, Stappenbeck et al, 2004);~* Veteran must meet DSM-IV criteria for current (past month) PTSD;~* Veteran consumed alcohol in the past 90 days;~* couple must be married to or living with their current partner for at least 1 year;~* Veteran agrees to a goal of abstinence from drugs at least for the duration of the 15-week study-based treatment;~* Veteran agrees to the goal of abstaining from alcohol or consuming alcohol within low risk drinking guidelines during the duration of the 15-week study-based counseling;~* Veteran agrees to forego other treatment for alcohol-related disorders except for self help meetings (e.g., AA) or treatment required for a clinical emergency or clinical deterioration for the duration of the 15-week study based treatment;~* Veteran agrees to forgo other PTSD treatment except for treatment required for a clinical emergency or clinical deterioration for the duration of the 15-week study based treatment;~* couple agrees to forgo other couple-based counseling for the duration of the 15-week study based treatment except for treatment required for a clinical emergency or clinical deterioration;~* partner does not meet DSM-IV criteria for current (past 12 month) substance use disorder (other than nicotine)~* partner does not meet DSM-IV criteria for current (past month) PTSD.~Exclusion Criteria:~* Veteran has dependence on alcohol or other drugs that requires inpatient treatment or medical detoxification (as indicated by daily heavy use or use to prevent or deal with withdrawal symptoms) - after completing detoxification, Veteran may be eligible for the study;~* Veteran or partner are at immediate risk for suicide or homicide (current plan or intent);~* Veteran or partner exhibit a history of suicide or homicide attempt in the past year;~* Veteran is participating in a methadone maintenance or suboxone maintenance program and is seeking treatment for adjunctive outpatient services;~* Veteran or partner meets DSM-IV criteria for a current organic mental disorder, schizophrenia, delusional (paranoid) disorder, or any of the other psychotic disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: CTAP (Type: EXPERIMENTAL): Couple-Based Treatment for Alcohol Use Disorders and PTSD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has chronic HCV infection genotype 1 with HCV RNA level \> 1,000 IU/mL~* Patients should not have had any previous treatment for hepatitis C~* Patient must have documentation of a liver biopsy within 2 years before the screening visit or the patient must agree to have a biopsy performed within the screening period~* Patients with cirrhosis should have serum alpha-fetoprotein (AFP) \<= 50 ng/mL. If AFP \> 50 ng/mL, absence of a mass must be demonstrated by ultrasound within the screening period~* A female patient of childbearing potential and a nonvasectomized male patient who has a female partner of childbearing potential must agree to the use of 2 effective methods of birth control from screening until 6 months (female patient) or 7 months (male patient) after the last dose of RBV.~Exclusion Criteria:~* Patient is infected or co-infected with HCV of another genotype than genotype 1 and/or patient is infected with more than one genotype subtype~* Patient has a pre-existing psychiatric condition~* Patient has history of decompensated liver disease or shows evidence of significant liver disease in addition to hepatitis C~* Patient has human immunodeficiency virus (HIV) or hepatitis B virus (HBV) co-infection~* Patient has active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 001 T(q8h) / PR (Type: EXPERIMENTAL): Telaprevir (T) 750 mg (2 oral tablets) every 8 hours for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
- 002 T(b.i.d.) / PR (Type: EXPERIMENTAL): Telaprevir (T) 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Hepatic Cirrhosis with ascites or lower extremities edema~2. Hospitalized patients~3. 18 years old\~75 years old~4. Inform Consent Form Signed~Exclusion Criteria:~1. Patients with any of the following diseases, complications or symptoms:~   * Hepatic encephalopathy (coma degree classification note 1 Grade 2 or above);~  * Malignant ascites;~  * Spontaneous bacterial peritonitis;~  * Likely to have gastrointestinal bleeding during the study period;~  * Heart failure (NYHA Note 2 Class Ⅲ andⅣ);~  * Anuria (daily urine output below 100mL);~  * Dysuria induced by urinary tract stenosis, calculus, or tumor.~2. Patients with any of the following history:~   * With gastrointestinal bleeding within 10 days prior to screening;~  * With cerebrovascular accident within 1 month prior to screening;~  * With gout attack within 1 month prior to screening;~  * With allergy or atopy to benzodiazepine drugs (benazepril hydrochloride, etc.).~3. Patients whose systolic blood pressure is below 90mmHg during screening;~4. Patients with abnormal values in the following lab examination indicators:~   Serum creatinine higher than 2.5 times the upper limit of normal range, serum Na+\>145mmol/L(or higher than the upper limit of normal range), serum K+\> 5.5 mmol/L, uric acid\>476µmol/L, child-Pugh score\>10~5. Patients ineligible for oral medication~6. Patients in pregnancy or lactation; female of childbearing potential not taking contraceptive measures;~7. Patients having taken blood products including albumin products within 4 days prior to application of investigational product;~8. Patients having participated in clinical trials of other drugs within 1 month prior to screening;~9. Patients used to participate in clinical trials of Tolvaptan and take the said drug;~10. Patients determined by the investigator as illegible for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tolvaptan 15mg tablet (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* documented inoperable, locally advanced, metastatic or recurrent non-squamous NSCLC;~* adequate liver and kidney function;~* women of childbearing potential must have a negative serum pregnancy test within 7 days of starting study treatment.~Exclusion Criteria:~* prior chemotherapy or treatment with another systemic cancer therapy;~* surgery (including open biopsy), significant traumatic injury, or radiotherapy within the last 4 weeks prior to first dose of study treatment;~* brain metastasis or spinal cord compression;~* fertile men, and women of childbearing potential, not using adequate contraception;~* treatment with any other investigational agent, or participation in another clinical trial, within 30 days prior to entering the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Free Venlafaxine Treatment for Marijuana Addiction and Depression - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets criteria for current marijuana addiction and reports marijuana as primary drug of abuse~* Currently meets criteria for major depression or dysthymic disorder and receive a score of greater than or equal to 12 on the Hamilton Depression Inventory~* Clinically depressed for at least 3 months during a period of active marijuana use~* Women of child-bearing age will be included provided that they are not pregnant, based on the results of a blood pregnancy done at the time of screening and agree to use a method of contraception with proven efficacy and not to become pregnant during the study. To confirm this, blood pregnancy tests will be repeated monthly. Women will be provided a full explanation of the potential dangers of pregnancy while on the study. If a woman becomes pregnant, the study medication will be discontinued.~Exclusion Criteria:~* Meets criteria for past manic or psychotic disorder, unless substance-related~* History of a seizure disorder~* Individuals with chronic organic mental syndrome~* Any significant risk for suicide based on current assessment and history of attempts~* History of allergic reaction to either Venlafaxine or Ven-XR~* Unstable physical disorders that might make participation hazardous, such as uncontrolled hypertension and tachycardia (SBP\>150, DBP \>90, or a sitting quietly HR\>100), acute hepatitis (patients with chronic mildly elevated transaminase levels (\<2x upper limit of normal are acceptable) or unstable diabetes~* History of failure to respond to a previous adequate trial of Venlafaxine of at least 300 mg. for at least a 6-week period~* Physical dependence on any other drugs (excluding nicotine) that would require medical detoxification~* Currently being prescribed psychotropic medication by another physician (in the last 3 weeks), except for acute treatment of insomnia.~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Venlafaxine (Type: ACTIVE_COMPARATOR): Venlafaxine
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of asthma \< 3 months~* Prescribed daily use of glucocorticosteroids for at least 3 months prior to Visit 1~Exclusion Criteria:~* Smoking history \> 10 pack-years~* Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to inclusion~* Any significant disease or disorder that my jeopardize the safety of the patient.~Additional inclusion and exclusion criteria will be evaluated by the investigator.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bilateral Prefrontal Modulation in Alcoholism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients between the age of 18 and 60 years;~* met criteria for alcohol dependence according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), as determined by clinical evaluation;~* in stable clinical condition with no need for inpatient care;~* able to read, write, and speak Portuguese; and~* no severe withdrawal signs or symptoms at baseline.~Exclusion Criteria:~* a condition of intoxication or withdrawal due to a substance other alcohol;~* unstable mental or medical disorder or substance abuse or addiction other than alcohol dependence, except nicotine and/or caffeine;~* a diagnosis of epilepsy, convulsions, or delirium tremens during abstinence from alcohol;~* a previous history of drug hypersensitivity or adverse reactions to diazepam or other benzodiazepines and haloperidol;~* any contraindication for electrical brain stimulation procedures such as electronic implants or metal implants;~* suspected pregnancy for female participants;~* any contraindication for magnetic resonance procedures such as electronic implants, metal implants, claustrophobia, or permanent make-up or tattoo received within the previous 3 months;~* the presence of vascular, traumatic, inflammatory, or tumor injuries detectable by CT examination.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- real tDCS (Type: EXPERIMENTAL): Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
- sham-tDCS (Type: SHAM_COMPARATOR): Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 20 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Staccato Loxapine in Agitated Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adult patients with schizophrenia and acute agitation~Exclusion Criteria:~* Agitation caused primarily by acute intoxication~* History of drug or alcohol dependence~* Treatment with benzodiazepines or other hypnotics within 4 hours prior to study drug administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Inhaled Loxapine 5 mg (Type: EXPERIMENTAL): Inhaled Loxapine 5 mg, may repeat x 1 or 2 after 2 hours
- Inhaled Loxapine 10 mg (Type: EXPERIMENTAL): Inhaled Loxapine 10 mg, may repeat x 1 or 2 after 2 hours
- Inhaled placebo (Type: PLACEBO_COMPARATOR): Inhaled Loxapine placebo, may repeat x 1 or 2 after 2 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete